Literature DB >> 28243796

Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis.

Nicola Veronese1, Claudio Luchini2, Marco Solmi3, Giuseppe Sergi4, Enzo Manzato4, Brendon Stubbs5,6,7.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a common condition in the elderly. A number of studies have investigated the relationship between MGUS and bone health outcomes including bone mineral density (BMD), osteoporosis and fractures, but no meta-analysis exists. We conducted a systematic review and exploratory meta-analysis comparing bone health outcomes in patients with MGUS. Two independent authors searched PubMed and Scopus from inception until 19 October 2016. A meta-analysis of cross-sectional and longitudinal studies investigating fractures and BMD was conducted. Standardised mean differences (SMD) ± 95% confidence intervals (CIs) were calculated for BMD, and risk ratios (RRs) were calculated for prevalent and incident fractures. Of 174 initial hits, 10 studies of moderate methodological quality were eligible, including 8711 individuals with MGUS vs. 52,865 controls. Compared to controls, subjects with MGUS showed significantly lower values for radial cortical volumetric BMD (1 study; SMD = -5.45, 95% CI: -7.24 to -3.66), but not at the lumbar spine, femoral neck or hip. The incidence of fractures was higher in people with MGUS (n = 7466) vs. controls (n = 52,304) (RR = 1.36, 95% CI 1.28-1.44, I 2 = 0%) over a median of 12.5-year follow-up. The incidence of vertebral fractures was particularly elevated (RR = 2.50, 95% CI 1.53-4.06) although limited to two studies. In conclusion, although with limitations, our preliminary meta-analysis suggests that patients with MGUS are at higher risk of fractures despite evidence for differences in BMD being equivocal. Future longitudinal research is required to confirm our findings and determine if fracture prevention interventions are warranted in people with MGUS.

Entities:  

Keywords:  Aging; Fractures; Monoclonal gammopathy of undetermined significance; Osteoporosis

Mesh:

Year:  2017        PMID: 28243796     DOI: 10.1007/s00774-017-0817-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  20 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance.

Authors:  Omer Dizdar; Mustafa Erman; Mustafa Cankurtaran; Meltem Halil; Zekeriya Ulger; Burcu Balam Yavuz; Servet Ariogul; Asli Pinar; Hakan Harputluoglu; Ayse Kars; Ismail Celik
Journal:  Ann Hematol       Date:  2007-09-14       Impact factor: 3.673

3.  Publication Bias: The Elephant in the Review.

Authors:  Jarrod E Dalton; Shari D Bolen; Edward J Mascha
Journal:  Anesth Analg       Date:  2016-10       Impact factor: 5.108

Review 4.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study.

Authors:  Bo Abrahamsen; Ivan Andersen; Susanne S Christensen; Jonna Skov Madsen; Kim Brixen
Journal:  BMJ       Date:  2005-03-14

7.  Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.

Authors:  Alvin C Ng; Sundeep Khosla; Natthinee Charatcharoenwitthaya; Shaji K Kumar; Sara J Achenbach; Margaret F Holets; Louise K McCready; L Joseph Melton; Robert A Kyle; S Vincent Rajkumar; Matthew T Drake
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

Review 8.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

9.  Bone disease in multiple myeloma.

Authors:  Matthew T Drake
Journal:  Oncology (Williston Park)       Date:  2009-12       Impact factor: 2.990

10.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

View more
  12 in total

1.  Vertebral fractures cascade: potential causes and risk factors.

Authors:  H Che; V Breuil; B Cortet; J Paccou; T Thomas; L Chapuis; F Debiais; N Mehsen-Cetre; R M Javier; S Loiseau Peres; C Roux; K Briot
Journal:  Osteoporos Int       Date:  2018-12-05       Impact factor: 4.507

2.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

3.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

4.  Bone Health and Survival in Women With Multiple Myeloma.

Authors:  Ashley E Rosko; Erinn M Hade; Wenjun Li; Steven Ing; Rebecca D Jackson; Electra D Paskett; Michelle J Naughton
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-06-08

5.  MGUS bone.

Authors:  Osamu Imataki; Makiko Uemura
Journal:  Oxf Med Case Reports       Date:  2019-08-28

Review 6.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

7.  Bone tissue quality in patients with monoclonal gammopathy of uncertain significance.

Authors:  Guillermina Orduna; Leonardo Mellibovsky; Eugenia Abella; Xavier Nogués; Roser Granero; Natalia García-Giralt; Marta Pineda-Moncusí; Roberto Güerri-Fernández; Daniel Prieto-Alhambra; Adolfo Díez-Pérez
Journal:  J Bone Miner Metab       Date:  2020-01-23       Impact factor: 2.626

8.  Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance.

Authors:  E M Stein; A Dash; M Bucovsky; S Agarwal; J Fu; S Lentzsch; E Shane
Journal:  Osteoporos Int       Date:  2018-11-28       Impact factor: 4.507

Review 9.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

10.  Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature.

Authors:  Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.